In this article, we will discuss Olaparib (Warnings-1). So, let’s get started. Myelodysplastic Syndrome/Acute Myeloid Leukemia Overall, the incidence of Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML) in patients treated with Olaparib monotherapy in clinical trials, including long-term follow up, was <1.5% (21/1680) and the majority of events had a fatal outcome. Of these, 19/21 patients had […]
Tag: Olaparib
In this article, we will discuss Olaparib (Dosage Strength). So, let’s get started. Dosage Strength Tablets: • 150 mg: green to green/grey, oval, bi-convex, film-coated, with debossment ‘OP150’ on one side and plain on the reverse side. • 100 mg: yellow to dark yellow, oval, bi-convex, film-coated, with debossment ‘OP100’ on one side and plain […]
In this article, we will discuss Olaparib (Dose Modifications-2). So, let’s get started. Dose Modifications for Patients with Renal Impairment Patients with mild renal impairment (CLcr 51-80 mL/min as estimated by Cockcroft-Gault equation) do not require an adjustment in Lynparza dosing. In patients with moderate renal impairment (CLcr 31-50 ml/min) the recommended dose reduction is […]
In this article we will discuss Olaparib (Usage-4)
In this article, we will discuss Olaparib (Dose Modifications-1). So, let’s get started. Dose Modifications for Use with CYP3A Inhibitors Avoid concomitant use of strong or moderate CYP3A inhibitors and consider alternative agents with less CYP3A inhibition. If a strong CYP3A inhibitor must be co-administered, reduce the Olaparib dose to 100 mg (one 100 mg […]
In this article, we will discuss Olaparib (Dose Adjustments). So, let’s get started. Dose Adjustments for Adverse Reactions To manage adverse reactions, consider interruption of treatment or dose reduction. The recommended dose reduction is 250 mg (one 150 mg tablet and one 100 mg tablet) taken twice daily, for a total daily dose of 500 […]